# Best Available Copy

Serial No. 10/038,984 Group No. 1635 Confirmation No. 9705



1 Publication number:

**0 318 281** A3

12

#### **EUROPEAN PATENT APPLICATION**

(1) Application number: 88311118.9

(5) Int. Cl.5: A61K 31/70

Date of filing: 24.11.88

Priority: 25.11.87 US 125098 09.09.88 US 242341

- ② Date of publication of application: 31.05.89 Bulletin 89/22
- Designated Contracting States:
   AT BE CH DE ES FR GB GR IT LI LU NL SE
- Date of deferred publication of the search report:
   10.10.90 Bulletin 90/41
- 71) Applicant: HEM RESEARCH, INC. 12280 Wilkins Avenue P.O. Box 2245 Rockville, MD 20852(US)
- (72) Inventor: Carter, William A. 1 Jaine Lane Birchrunville Pennsylvania 19421(US)
- Representative: Hallybone, Huw George et al CARPMAELS AND RANSFORD 43 Bloomsbury Square London WC1A 2RA(GB)
- (9) Use of dsRNA in the prevention of viral escape.
- (9) dsRNA reduces the phenomenon of viral escape and cellular damage attendant thereto. Viral escape is a process by which a virus or intracellular pathogen alters its host range or indirectly alters its susceptibility to antiviral or immunological therapies. Viruses do so by causing specific changes in their genomic/antigenic composition and/or by causing the elaboration of factors which enhance destructiveness of cells and their ability to multiply progeny virus. Animals susceptible to viral infections and pathology secondary to antigenic drift may have damage reduced by exposing them to dsRNA which prevents or substantially minimizes viral escape brought about through these mechanisms of molecular rearrangement and/or elaboration of factors which preak down the natural host defenses.

EP 0 318 281 A3

### Best Available Copy



#### PARTIAL EUROPEAN SEARCH REPORT

Application number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 88 31 1118

	DOCUMENTS CONS	IDERED TO BE	RELEVANT		
Category	Citation of document wi	th indication, where app vant passages	ropriata,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CI.4)
E	EP-A-0 300 680 (		CH INC.)	1-9	A 61 K 31/70
	- The whole dock	anteric		1-9	
E	EP-A-0 308 066 (	(HEM RESEAR	CH INC.)		
	* The whole docu	ument *		1-9	
D,P,	EP-A-0 286 224(F				
	* The whole docu	ıment *		1-9	
D,Y	EP-A-0 213 921 (	HEM RESEARC	CH INC.)	į	TECHNICAL FIELDS
	* The whole docu	ument *		1-9	SEARCHED (Int. Cl.4)
			•/•		
-	MPLETE SEARCH		A 61 K C 07 H		
the provision a mea Glaims se Glaims se Glaims no Reason fo Claim rath	ch Division considers that the preseisions of the European Patent Conveisions that completely: 5-9 inserched incompletely: 1-4 of searched: 1-4 of the limitation of the search:  ms 1-4: State bicer modes of acticitical applications	ological med	the claims.	or	
Place of search Date of completion of the search				Examiner	
1,000 01 000 01		09-07-1	09-07-1990 FOE		RSTER
CATEGORY OF CITED DOCUMENTS  X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document					but published on, or Dication reasons

## Best Available Copy



## PARTIAL EUROPEAN SEARCH REPORT EP 88 31 3338 -2-

	DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (Int. CI.4)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
x	THE LANCET, no. 1/8545, June 6, 1987, pages 1286-1292; W.A. CARTER et al.: "Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex"		
	* The whole article *	1-9	
	<del></del>		
D,P, A	THE LANCET, no. 1/8589, April 9, 1988, pages 790-794; W.E. ROBINSON Jr. et al.: "Antibody dependent enhancement of human immunodeficiency virus type 1 infection"		TECHNICAL FIELDS SEARCHED (Int. CI.4)
	* The whole article *	1-9	
A	PROC. NATL. ACAD. SCI. USA, vol. 83, September 1986, pages 7023-7027; W.G. ROBEY et al.: "Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody"		
	* The whole article *	1-9	
A	PROC. NATL. ACAD. SCI. USA, vol. 85, July 1988, pages 5200-5204; P.W. BERMAN et al.: "Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120"		
	* The whole article *	1-9	
	·		
PO Form	1505.3 06.78		